SecurityAFMD / Affimed N.V. (N01045108)
Institutional Owners44
Institutional Shares27,426,036
Institutional Value$ 50,738,000 USD

Institutional Stock Ownership and Shareholders()

AFMD / Affimed N.V. Institutional Ownership

Affimed N.V. (NASDAQ:AFMD) has 44 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 27,426,036 shares. Largest shareholders include Wellington Management Group LLP, NEA Management Company, LLC, Brookside Capital Management Llc, Millennium Management Llc, New Leaf Venture Partners, L.L.C., Tekla Capital Management LLC, Kennedy Capital Management, Inc., Telemetry Investments, L.L.C., Sabby Management, LLC, and Baker Brothers Advisors LP.
Affimed N.V. (NASDAQ:AFMD) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/afmd"><img src="https://images.fintel.io/us-afmd-so.png" alt="AFMD / Affimed N.V. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-14 13F-HR MORGAN STANLEY 153,188 327,070 113.51 199 605 204.02
2018-05-15 13F-HR Iguana Healthcare Management, LLC 0 300,000 0 555
2018-05-15 13F-HR PIONEER INVESTMENT MANAGEMENT INC 50,600 37,100 -26.68 66 69 4.55
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 1,000 14,400 1,340.00 1 27 2,600.00
2018-05-11 13F-HR MACQUARIE GROUP LTD 6,500 0 -100.00 8 0 -100.00
2017-10-26 13F-HR Acrospire Investment Management LLC 658 0 -100.00 1 0 -100.00
2018-05-15 13F-HR/A Sabby Management, LLC 0 425,463 0 787
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 104,512 0 -100.00 136 0 -100.00
2018-05-14 13F-HR KENNEDY CAPITAL MANAGEMENT, INC. 740,783 1,370
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 0 2,557,311 0 4,731
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 0 24,374 0 45
2018-05-15 13F-HR BROOKSIDE CAPITAL MANAGEMENT LLC 3,209,013 3,209,013 0.00 4,172 5,937 42.31
2018-06-28 13F-HR/A BROWN ADVISORY INC 50,000 92
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 40,385 0 -100.00 53 0 -100.00
2018-05-15 13F-HR Telemetry Investments, L.L.C. 569,774 545,000 -4.35 741 1,008 36.03
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Call 15,500 29
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 13 8,000 61,438.46 0 13
2018-04-30 13F-HR TCI Wealth Advisors, Inc. 500 0 -100.00 1 0 -100.00
2018-05-15 13F-HR Wellington Management Group LLP 5,347,910 6,630,192 23.98 6,953 12,266 76.41
2018-05-11 13F-HR CITADEL ADVISORS LLC Call 15,500 29
2018-05-10 13F-HR NEA Management Company, LLC 3,888,888 5,138,888 32.14 5,056 9,507 88.03
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 0 592 0 1
2018-05-15 13F-HR Baker Brothers Advisors LP 400,000 400,000 0.00 520 740 42.31
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 3,000 0 -100.00 4 0 -100.00
2018-05-15 13F-HR UBS Group AG 400 797 99.25 1 2 100.00
2018-05-14 13F-HR DRW Securities, LLC 110,000 204
2018-05-15 13F-HR Sofinnova Ventures Inc 110,834 205
2018-05-14 13F-HR Virtu Financial LLC 85,562 22,516 -73.68 111 42 -62.16
2018-05-15 13F-HR New Leaf Venture Partners, L.L.C. 2,250,000 4,163
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. 4,381 2,000 -54.35 6 4 -33.33
2018-05-14 13F-HR HRT FINANCIAL LLC 15,038 27
2018-05-08 13F-HR US BANCORP \DE\ 24,000 24,000 0.00 31 44 41.94
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 10,000 10,000 0.00 13 18 38.46
2018-05-01 13F-HR WEDBUSH SECURITIES INC 12,000 0 -100.00 16 0 -100.00
2018-04-18 13F-HR Creative Planning 100,000 106,900 6.90 130 198 52.31
2018-05-15 13F-HR DEUTSCHE BANK AG\ 29,700 76,467 157.46 38 141 271.05
2018-05-15 13F-HR Cvi Holdings, Llc 360,455 667
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 8 9 12.50 0 0
2018-05-15 13F-HR Moore Capital Management, LP 125,000 0 -100.00 163 0 -100.00
2018-05-15 13F-HR Point72 Asset Management, L.P. 0 250,000 0 463
2018-05-15 13F-HR Cubist Systematic Strategies, LLC 18,593 0 -100.00 24 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 13,385 64,958 385.30 17 120 605.88
2018-04-26 13F-HR SIMPLEX TRADING, LLC Put 49 1 -97.96 6 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 468,237 0 -100.00 1,302 0 -100.00
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 500 500 0.00 1 1 0.00
2018-05-15 13F-HR OXFORD ASSET MANAGEMENT 81,661 0 -100.00 104 0 -100.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 175,000 175,000 0.00 228 324 42.11
2018-05-15 13F-HR PERCEPTIVE ADVISORS LLC 668,214 0 -100.00 869 0 -100.00
2018-04-26 13F-HR SIMPLEX TRADING, LLC 1,612 0 -100.00 2 0 -100.00
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 11,021 11,021 0.00 14 20 42.86
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 0 43,000 0 80
2018-05-15 13F-HR ORBIMED ADVISORS LLC 326,650 326,650 0.00 425 604 42.12
2018-05-14 13F-HR Renaissance Technologies LLC 62,100 127,900 105.96 81 237 192.59
2018-05-10 13F-HR JP Morgan Chase & Co 22,133 0 -100.00 29 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 61,234 83,427 36.24 80 154 92.50
2018-05-14 13F-HR Eversept Partners, Llc 386,862 716
2018-05-14 13F-HR Tekla Capital Management LLC 1,405,324 1,805,324 28.46 1,827 3,340 82.81
2018-05-11 13F-HR MUHLENKAMP & CO INC 61,000 0 -100.00 79 0 -100.00
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 37,500 42,300 12.80 86 78 -9.30
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 248,326 319,871 28.81 323 592 83.28
2018-07-09 13F-HR Advocacy Wealth Management Services, LLC 1,000 1,000 0.00 2 2 0.00
2018-05-15 13F-HR Crestline Management, LP 334,166 618
2018-05-15 13F-HR RBF Capital, LLC 32,564 32,564 0.00 42 62 47.62
2018-05-10 13F-HR Spark Investment Management LLC 27,700 0 -100.00 36 0 -100.00
2018-05-11 13F-HR KNOTT DAVID M 24,000 44
AFMD : Affimed N.V. Stock Analysis and Research Report

2017-10-15 - Asif

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Its proprietary, next-generation bispecific antibodies, which it call TandAbs because of their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells. The company TandAbs have the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Due to their novel tetravalent architecture (which provides for four binding domains), its TandAbs bind to their targets with high affini...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

42m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Affimed Sinks Despite Positive Interim Results

2018-06-15 247wallst
Affimed N.V. (NASDAQ: AFMD) shares dropped sharply early on Friday after the company released new results from its early stage trial with Keytruda. Affimed presented new interim data from the Phase 1b dose escalation study evaluating AFM13, its lead NK cell engager candidate, at the European Hematology Association (EHA) 23rd Congress in Stockholm, Sweden (102-8)

CUSIP: N01045108